3 stories mentioning HKG:0874Updated 20d ago
Every FINWIRES story that references HKG:0874, newest first.
Guangzhou Baiyunshan Pharmaceutical (SHA:600332, HKG:0874) branch entity, Baiyunshan Pharmaceutical General Factory, received drug registration from China's medical products regulator for oseltamivir phosphate for oral suspension.The drug treats influenza A and B, according to a Tuesday filing with the Shanghai bourse.
China's drug regulator granted Guangzhou Baiyunshan Pharmaceutical (SHA:600332, HKG:0874) a supplemental drug approval for its cefuroxime sodium injection and candesartan cilexetil tablets, according to a Tuesday filing with the Shanghai bourse.The approvals cover supplementary research.Cefuroxime sodium is indicated for acute respiratory, urinary tract, and other bacterial infections, whileCandesartan cilexetil is indicated for hypertension.
Guangzhou Baiyunshan Pharmaceutical's (HKG:0874, SHA:600332) net profit attributable to shareholders fell 2.1% to 1.78 billion yuan in the first quarter, from 1.82 billion yuan a year earlier, according to a Monday Hong Kong bourse filing.Earnings per share came in at 1.097 yuan, compared with 1.120 yuan in the prior-year period.Income from operations rose 3.6% to 23.3 billion yuan from 22.5 billion yuan a year earlier.The pharmaceutical company's Hong Kong shares rose 2% during Tuesday morning's trade, while its Shanghai-listed shares were up 3%
